Analysts Cross Fingers for 2018 Return of BioPharma Mega-MergersBy
Tax reform may be key driver to M&A resurgence in 2018
Specter of drug pricing reform may revive uncertainty
Wall Street is holding its breath for the rekindling of mergers and acquisitions across the biotechnology and pharmaceutical sector after 2017 led to a pause in deal-making. Tax reform, particularly a lower levy on U.S. companies’ overseas cash, may be the key to driving the return of M&A in 2018. “Choppy waters will likely continue, unless M&A saves the day,” RBC analysts led by Brian Abrahams wrote in their look ahead to next year.
Goldman analysts led by Jami Rubin see a lower tax rate on repatriated cash, yielding about $160 billion across the health-care sector. That extra cash may be used for “aggressive capital allocation”; in addition to M&A, that cash could also be spent on buybacks and dividends, or a combination of the three Goldman predicted.
Pfizer Inc., instead of announcing a new mega-deal, is ending the year by starting a $10 billion share buyback program and an increased dividend. Still, some analysts are hopeful after Roche’s $1.7 billion bid earlier today for Ignyta. JPMorgan’s January healthcare conference in San Francisco is often a platform for partnerships and deals to be announced.
Concern also abound that Democratic wins in midterm elections may once again raise a rallying cry around drug pricing reform, driving a return to uncertainty in the sector similar to years past when Hillary Clinton’s tweets rocked the market.
- “Stocks – as well as investor sentiment – continue to whipsaw wildly from one day to the next, making it virtually impossible to see which direction will hold as we move into 2018”
- Tax reform may give biotech sector a boost in the first half of the year, although there may be more focus on partnering over traditional M&A, which may frustrate investors and lead to more exits
- Earnings expectations may be a challenge and could drive investor money toward small- to mid-cap companies, if not out of biotech entirely
- Key catalysts that may drive sector sentiment include results from Incyte Corp in melanoma, Alexion Pharmaceuticals Inc. in a very rare blood disorder known as paroxysmal nocturnal hemoglobinuria, and Biogen Inc. data in Alzheimer’s
- “We advocate selectivity going into 2018 following a solid rebound for health care in 2017,” possibility of Democratic wins in midterm elections may “add uncertainty” as the debate over drug pricing reform could reignite under Democrats
- Sector growth expectations “are now measured” and likely to be no better than the broader market; U.S. equity strategist calls for “an earnings-driven bull market,” hinged on tax reform, continuing in 2018
- “Seeing early signs of a bottoming of the beleaguered generic sector with commentary on rationalization of manufacturing capacity and portfolios from the largest players” including Teva Pharmaceutical Industries Ltd. and Novartis AG
- New ideas for conviction list; BioMarin Pharmaceutical Inc., Alnylam Pharmaceuticals Inc. and Hologic Inc.
- “We see opportunity in high conviction ideas given limited 2018 investor conviction. Potential M&A from tax reform is balanced by a potential increase in political noise, but high sector innovation remains encouraging.”
- Amgen Inc. may benefit the most from tax reform, bringing back about $39 billion from overseas cash; Biogen Inc., Celgene Corp., Alexion Pharmaceuticals Inc. and Gilead Sciences Inc. are the most likely to make deals to pad their pipelines
- There’s a lack of clinical catalysts for large-caps next year, focus for Gilead likely on reimbursement complications and patient demand for its CAR-T therapy while Vertex Pharmaceuticals Inc. investors are awaiting the company’s triple-drug cocktail for cystic fibrosis to reach the market
- Among small- to mid-caps with potential catalysts that may move shares 20 percent or more are: Biohaven Pharmaceutical Holding Company Ltd. with late-stage migraine therapy results in 1Q, Portola Pharmaceuticals Inc. with regulatory approval decisions on Bevyxxa manufacturing and AndexXa, Global Blood Therapeutics Inc. on initial data from “Hope” study in first half and DBV Technologies with an update on the regulatory path forward for its peanut allergy treatment, Viaskin
- 2018 viewed as a “repair year” ahead of large cap biotech new product cycle in 2019
- Key catalysts ahead include; Gilead results for its autoimmune drug with Galapagos NV and in a liver disease known as NASH; Celgene data for ozanimod in ulcerative colitis; Biogen’s Alzheimer’s data and results and commercial drug launch for Vertex’s triple combo
- Celgene may use its $8 billion overseas cash and $50 billion in free cash flow to buy more assets in the coming years
- M&A will be key for generalists to return to the biotech sector with repatriation of overseas cash a potential trigger; “if M&A fails to materialize, selectivity may again become increasingly important”
- Sees estimates for earnings “broadly achievable” after a rough third quarter for biotech bellwethers
- Clinical catalysts are “an omnipresent risk”
- Top long ideas include Celgene, Puma Biotech while shorts include Amgen and Tesaro
- “We believe industry consolidation is inevitable but our caution is driven by the fact that we can’t predict when this important trend will play out.”
- Large caps viewed as “better source” of investments ideas than mega-caps
- Top picks for next year are Incyte Corp, Vertex, Sarepta Therapeutics Inc., Puma Biotechnology Inc., and Tesaro Inc.